> top > docs > PMC:7784824 > spans > 15551-16463 > annotations

PMC:7784824 / 15551-16463 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
302 691-696 Gene denotes Prima Gene:145270
334 34-42 Species denotes patients Tax:9606
335 150-160 Species denotes SARS-CoV-2 Tax:2697049
336 242-250 Species denotes patients Tax:9606
337 268-276 Species denotes patients Tax:9606
338 327-334 Species denotes patient Tax:9606
339 362-370 Species denotes patients Tax:9606
340 419-427 Species denotes patients Tax:9606
341 473-481 Species denotes patients Tax:9606
342 627-635 Species denotes patients Tax:9606
343 753-763 Species denotes SARS-Cov-2 Tax:2697049
344 845-855 Species denotes SARS-CoV-2 Tax:2697049
345 670-680 Species denotes SARS-CoV-2 Tax:2697049
346 99-107 Disease denotes COVID-19 MESH:C000657245
347 553-573 Disease denotes respiratory symptoms MESH:D012818

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T171 0-118 Sentence denotes In our institution a total of 145 patients were hospitalized with an in-house laboratory confirmed COVID-19 diagnosis.
T172 119-257 Sentence denotes In this group, the presence of SARS-CoV-2 was confirmed using RT-PCR on the first nasopharyngeal and/or throat swab in 132 patients (91%).
T173 258-353 Sentence denotes Another 4 patients were diagnosed with a second nasopharyngeal and 1 patient with an anal swab.
T174 354-412 Sentence denotes Next, 5 patients were found to be positive on BAL samples.
T175 413-466 Sentence denotes Three patients remained negative on repetitive swabs.
T176 467-620 Sentence denotes These patients were not eligible for a BAL sampling procedure or did not present with respiratory symptoms and as such serological testing was performed.
T177 621-712 Sentence denotes All 3 patients were found to be positive for IgG SARS-CoV-2 serology (Prima Professional®).
T178 713-912 Sentence denotes Given the high pre-test probability for SARS-Cov-2 in this prospective cohort and repetitive testing, the added diagnostic value of SARS-CoV-2 serology in providing a diagnosis in this cohort was 2%.